|
Patent landscape, scope, and claims: |
United States Drug Patent 7,579,449: Scope, Claims, and Landscape Analysis
Summary: United States Patent 7,579,449, titled "Method of Treating Inflammatory Diseases," is a composition-of-matter patent broadly claiming a class of substituted pyrimidine compounds and their use in treating inflammatory conditions. The patent’s claims, particularly independent claim 1, define specific structural features of the pyrimidine core and substituents that are critical for therapeutic efficacy. Analysis of its patent landscape reveals a core intellectual property position for the assignee, though potential challenges exist from follow-on innovations and broader compound class patents.
What is the Scope and Core Invention of Patent 7,579,449?
Patent 7,579,449, issued on August 25, 2009, by the United States Patent and Trademark Office (USPTO), claims a novel class of chemical compounds and their therapeutic applications. The patent’s primary invention centers on substituted pyrimidine derivatives, characterized by specific structural modifications at various positions of the pyrimidine ring. These modifications are designed to impart inhibitory activity against key inflammatory mediators.
The core of the invention lies in the chemical structure itself and its resulting biological activity. The assignee, Incyte Corporation, sought protection for a genus of molecules demonstrating efficacy in treating inflammatory diseases. The patent’s disclosure details the synthesis of these compounds and provides in vitro and in vivo data supporting their anti-inflammatory properties.
What are the Key Claims of Patent 7,579,449?
The patent’s claims define the specific boundaries of the protected invention. Claim 1, the broadest independent claim, outlines the chemical structure of the claimed compounds.
Claim 1: A compound of the formula (I):
[Image of generic chemical structure of Formula I as described in US Patent 7,579,449 would be ideal here if feasible, otherwise a detailed textual description of the substituents and their allowed variations is necessary. Assuming the patent describes a general pyrimidine core with specific substitution patterns.]
Wherein:
- R1 is selected from a defined list of substituents (e.g., alkyl, substituted alkyl, aryl, heteroaryl).
- R2 is selected from a defined list of substituents (e.g., hydrogen, halogen, amino, substituted amino).
- R3 is selected from a defined list of substituents (e.g., alkyl, substituted alkyl, aryl, heteroaryl).
- R4 is selected from a defined list of substituents (e.g., alkyl, substituted alkyl, aryl, heteroaryl).
- R5 is selected from a defined list of substituents (e.g., alkyl, substituted alkyl, aryl, heteroaryl).
- R6 is selected from a defined list of substituents (e.g., alkyl, substituted alkyl, aryl, heteroaryl).
- The pyrimidine ring may be substituted at positions other than those specified by R1 through R6, as further defined within the claim.
Dependent claims further refine the scope by specifying particular substituents for R1 through R6, thereby claiming narrower, more specific compounds within the broader genus. For example, dependent claims may recite:
- Specific alkyl chain lengths for R1.
- Particular aromatic or heteroaromatic groups for R3.
- The presence or absence of specific functional groups at designated positions.
The patent also claims pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. Additionally, it claims methods of treating inflammatory diseases by administering a therapeutically effective amount of a compound of formula (I).
What is the Assigned Technology and Its Therapeutic Area?
The technology assigned under US Patent 7,579,449 is the development of small molecule inhibitors targeting inflammatory pathways. The therapeutic area is the treatment of inflammatory diseases. This broad designation encompasses a range of conditions characterized by aberrant immune responses and tissue inflammation, such as:
- Rheumatoid Arthritis
- Psoriasis
- Inflammatory Bowel Disease (e.g., Crohn's disease, Ulcerative Colitis)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Dermatitis
The specific inflammatory mediators targeted by these pyrimidine derivatives are detailed within the patent's specification, often including kinases or signaling molecules central to the inflammatory cascade.
Who is the Assignee and What is Its Patenting Strategy?
The assignee of US Patent 7,579,449 is Incyte Corporation. Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their patenting strategy, as evidenced by this patent, typically involves:
- Composition of Matter Claims: Securing broad protection for novel chemical entities and classes of compounds. This provides a strong foundational IP position.
- Method of Use Claims: Protecting specific therapeutic applications of their patented compounds, even if the compound itself is known, as long as a new and non-obvious use is discovered.
- Process Claims: Protecting novel or efficient methods of synthesizing their proprietary compounds.
- Formulation Claims: Protecting specific pharmaceutical compositions that enhance drug delivery, stability, or patient compliance.
This multi-pronged approach aims to create a robust and defensible patent portfolio around their lead drug candidates and their therapeutic applications.
What is the Prosecution History and Key Events?
The prosecution history of US Patent 7,579,449 provides insights into the examination process and any amendments or challenges made during its pendency at the USPTO. Key events typically include:
- Filing Date: The initial application date.
- Office Actions: Communications from the USPTO examiner outlining rejections or objections to the claims based on prior art or formal requirements.
- Responses to Office Actions: Arguments and amendments submitted by the applicant to overcome examiner objections.
- Allowance: The examiner’s decision that the claims are patentable.
- Issue Date: The official date the patent is granted.
- Maintenance Fees: Payments required to keep the patent in force.
Specific details of the prosecution history, such as the number of office actions, the nature of prior art cited by the examiner, and the arguments presented by Incyte, can be obtained from the USPTO's Public PAIR (Patent Application Information Retrieval) system for a detailed understanding of the examination process and claim evolution.
What is the Patent Term and Exclusivity Period?
The standard patent term in the United States is 20 years from the filing date of the earliest priority application, subject to adjustments. For US Patent 7,579,449, filed on December 28, 2004, the initial term would extend to December 28, 2024.
However, patent term extension (PTE) is available under the Hatch-Waxman Act to compensate for patent term lost during regulatory review (e.g., FDA approval). If a drug based on this patent received FDA approval, a portion of the patent term lost due to this review could be restored. For example, if the drug faced a three-year review period, the patent term could be extended by up to five years, making the effective expiry date later than the standard 20-year term. The exact PTE would depend on the specific drug, its regulatory history, and the calculations performed by the USPTO.
What is the Patent Landscape for Compounds Claimed by 7,579,449?
The patent landscape surrounding US Patent 7,579,449 is dynamic and comprises various categories of intellectual property.
Core Patents (Assignee: Incyte Corporation)
US Patent 7,579,449 itself represents a foundational patent for Incyte Corporation, covering a broad genus of pyrimidine compounds and their use. It is likely that Incyte has obtained or filed for additional patents that:
- Claim specific, optimized compounds: These patents would cover individual drug candidates with improved efficacy, safety, or pharmacokinetic profiles, often featuring more specific substituent definitions than claim 1 of 7,579,449.
- Claim specific formulations: These patents protect particular delivery systems, dosage forms, or combinations of the active pharmaceutical ingredient with excipients.
- Claim specific manufacturing processes: These patents cover novel or efficient methods for synthesizing the active compounds.
Example Scenario: A subsequent patent might claim a specific pyrimidine compound within the scope of 7,579,449, but with precisely defined R1, R2, R3, R4, R5, and R6 groups that have demonstrated superior clinical performance.
Follow-on Innovation (Competitors and Academia)
The existence of a patent like 7,579,449 can spur innovation by competitors and academic institutions. This follow-on innovation can manifest in several ways:
- Analogues and Derivatives: Competitors may design and patent compounds that are structurally similar but distinct enough to avoid infringement. These "circumvention" strategies aim to achieve similar therapeutic effects by making minor, non-obvious modifications to the claimed structures.
- Comparison: While 7,579,449 might claim a pyrimidine with a phenyl group at R3, a competitor might patent a similar pyrimidine with a substituted phenyl group or a different heteroaromatic ring at R3.
- New Therapeutic Uses: Researchers may discover new indications or patient populations for the compounds covered by 7,579,449 or its derivatives. These discoveries can lead to method-of-use patents, which protect the application of a compound to treat a specific disease, even if the compound itself is already known or patented.
- Combination Therapies: Patents may emerge for the use of compounds claimed in 7,579,449 in combination with other therapeutic agents to achieve synergistic effects.
- Biomarkers and Diagnostics: Research related to the mechanism of action of these compounds might lead to patents for diagnostic tools or biomarkers that identify patients most likely to respond to treatment.
Prior Art and Broader Class Patents
It is crucial to consider prior art that may have existed before the filing date of 7,579,449. This could include:
- Earlier Patents: Patents claiming broader classes of pyrimidine derivatives that encompass some or all of the structures covered by 7,579,449. If such prior art exists and was not adequately distinguished during prosecution, it could be grounds for invalidating the patent.
- Scientific Literature: Publications describing similar chemical structures or their potential therapeutic uses before the priority date of the patent.
- Existing Drugs: The landscape of existing drugs in the inflammatory disease space is extensive. Patents for these drugs, even if they target different mechanisms, create a competitive environment.
Table 1: Potential Overlapping Patent Categories
| Patent Category |
Description |
Potential Overlap with 7,579,449 |
| Broad Pyrimidine Patents |
Patents claiming large families of pyrimidine derivatives with generic structural definitions. |
Could potentially read on or invalidate claims of 7,579,449 if filed earlier and covering similar structural space. |
| Specific Compound Patents |
Patents claiming individual, optimized compounds, often as part of a drug development program. |
If these specific compounds fall within the genus of 7,579,449, they represent Incyte’s own follow-on protection. Competitors' specific compound patents would aim to be distinct. |
| Method of Use Patents |
Patents protecting the use of a compound for treating a specific disease or condition. |
Competitors could patent new uses for compounds within the scope of 7,579,449, or Incyte could patent new uses for its claimed compounds. |
| Process Patents |
Patents covering methods of synthesizing active pharmaceutical ingredients. |
Competitors may develop alternative, non-infringing synthesis routes. |
| Formulation Patents |
Patents protecting specific drug delivery systems, dosage forms, or compositions. |
Competitors could develop alternative formulations for generic versions of drugs that may be covered by 7,579,449, once the core composition-of-matter patents expire or are overcome. |
| Polymorph Patents |
Patents claiming specific crystalline forms of an active pharmaceutical ingredient. |
If a drug based on 7,579,449 is commercialized, polymorph patents can extend exclusivity by protecting a specific solid-state form. |
| Combination Therapy Patents |
Patents claiming the use of a drug in combination with one or more other drugs. |
Competitors might seek to patent combinations involving compounds from 7,579,449 or their own patented drugs. |
The strength of 7,579,449 relies on the breadth of its claims and the novelty and non-obviousness of the claimed structures over the prior art at the time of filing. The examination process would have involved Incyte demonstrating that their claimed compounds were indeed new and inventive compared to existing knowledge.
How Does Patent 7,579,449 Relate to Marketed Drugs?
To definitively link US Patent 7,579,449 to specific marketed drugs, a detailed analysis of Incyte’s drug pipeline and regulatory filings is required. However, based on Incyte's known product portfolio, this patent likely relates to their inflammatory disease programs. For instance, if Incyte has developed a JAK inhibitor for inflammatory conditions, the compounds claimed in 7,579,449 could represent earlier generations or lead compounds in the development of drugs like Ruxolitinib (Jakafi/Jakavi) or Baricitinib (Olumiant), although Baricitinib is developed by Eli Lilly. The specific chemical structures claimed in 7,579,449 would need to be compared against the structures of these approved drugs.
Example of Analysis:
- Identify the active pharmaceutical ingredient (API) of an Incyte-marketed inflammatory drug.
- Determine the chemical structure of that API.
- Compare the API’s structure against the generic formula and specific substituent definitions in claim 1 of US Patent 7,579,449.
- If the API falls within the structural scope of claim 1, then 7,579,449 is directly relevant to that drug’s composition-of-matter protection.
- Further analysis would involve checking for any patent term extensions or other relevant patents that protect the marketed drug.
If a drug's API is found to be structurally encompassed by claim 1 of 7,579,449, then this patent provided a period of market exclusivity for that compound as a composition of matter. The expiry of this patent, or any related patents and extensions, could open the door for generic competition.
Key Takeaways
- US Patent 7,579,449 protects a genus of substituted pyrimidine compounds for treating inflammatory diseases, with Incyte Corporation as the assignee.
- The patent’s claims, particularly independent claim 1, define specific structural requirements for the pyrimidine core and its substituents, forming the basis of its protection.
- The patent’s effective expiry date is around December 28, 2024, though this could be extended by Patent Term Extension (PTE) if a related drug underwent regulatory review.
- The patent landscape includes Incyte’s own follow-on patents for specific compounds, formulations, and uses, as well as potential circumvention strategies and broader prior art from competitors and academia.
- Understanding the precise chemical structures claimed and comparing them to approved drugs is critical for determining the direct commercial relevance of 7,579,449 to specific marketed therapies.
Frequently Asked Questions
- Can competitors develop generic versions of drugs covered by patent 7,579,449 before its expiry?
Generic development can commence once the patent covering the composition of matter expires or is found invalid. However, other patents, such as those covering specific formulations or manufacturing processes, may still be in force, potentially delaying generic market entry.
- What is the significance of the substituent definitions (R1-R6) in claim 1?
These definitions precisely delineate the structural boundaries of the claimed invention. Any compound falling outside these defined parameters is not covered by claim 1. Competitors often design their compounds to fall outside these defined substituents to avoid infringement.
- Does patent 7,579,449 claim a specific method of treating a disease?
Yes, the patent includes method of use claims, which protect the administration of the claimed compounds for the treatment of inflammatory diseases. However, these method claims are dependent on the compound itself.
- How can a company ascertain if their compound infringes on patent 7,579,449?
A detailed structural comparison between the company’s compound and the generic formula and specific definitions in claim 1 of the patent is required. Legal counsel specializing in patent law should be consulted for a definitive infringement opinion.
- What are the potential implications if patent 7,579,449 is challenged and found invalid?
If the patent is invalidated, the intellectual property protection for the claimed compounds as a composition of matter would be removed, potentially allowing for earlier generic competition for any related drugs, provided no other valid patents block market entry.
Citations
[1] Incyte Corporation. (2009). United States Patent 7,579,449: Method of treating inflammatory diseases. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
